Download PDF
Semin Vasc Med 2003; 03(4): 355-362
DOI: 10.1055/s-2004-815693
ETIOLOGY OF ACS

Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Endothelial Dysfunction as a Predictor of Acute Coronary Syndromes

Krishna Kathir, Mark  R. Adams
  • Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
Further Information

Publication History

Publication Date:
03 February 2004 (online)

    Permissions and Reprints

ABSTRACT

Endothelial dysfunction is a key early event in atherogenesis and is integral in the onset of acute coronary syndromes. Disruption of the normal endothelial functions leads to loss of vasomotor control, reduced production of nitric oxide, formation of a procoagulant surface, and promotion of inflammation. These events may lead to destabilization of atherosclerotic plaques and the onset of acute coronary syndromes. There are several direct and indirect ways of assessing endothelial dysfunction in vivo. Several of these measures of endothelial dysfunction have been shown to correlate with increased risk of adverse cardiovascular outcomes.

KEYWORDS

Endothelium - acute coronary syndrome - atherosclerosis

REFERENCES

  • 1 Palmer R M, Ashton D S, Moncada S. et al . Vascular endothelial cells synthesize nitric oxide from L-arginine.  Nature . 1988;  333 664-666
    CrossrefPubMedGoogle Scholar
  • 2 Bassenge E, Heusch G. Endothelial and neuro-humoral control of coronary blood flow in health and disease.  Rev Physiol Biochem Pharmacol . 1990;  116 77-165
    PubMedGoogle Scholar
  • 3 Arnold W P, Mittal C K, Katsuki S. et al . Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations.  Proc Natl Acad Sci USA . 1977;  74 3203-3207
    PubMedGoogle Scholar
  • 4 Dinerman J L, Mehta J L. Endothelial, platelet and leukocyte interactions in ischemic heart disease: insights into potential mechanisms and their clinical relevance.  J Am Coll Cardiol . 1990;  16 207-222
    PubMedGoogle Scholar
  • 5 Boulanger C M, Luscher T F. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide.  J Clin Invest . 1990;  85 587-590
    CrossrefPubMedGoogle Scholar
  • 6 De Caterina R, Libby P, Peng H-B. et al . Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.  J Clin Invest . 1995;  96 60-68
    PubMedGoogle Scholar
  • 7 Moncada S, Herman A G, Higgs E A. et al . Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium.  Thromb Res . 1977;  11 323-344
    CrossrefPubMedGoogle Scholar
  • 8 Cody R J. The potential role of endothelin as a vasoconstrictor substance in congestive heart failure.  Eur Heart J . 1992;  13 1573-1578
    PubMedGoogle Scholar
  • 9 Rubanyi G M. The role of endothelium in cardiovascular homeostasis and diseases.  J Cardiovasc Pharmacol . 1993;  22 S1-S14
    PubMedGoogle Scholar
  • 10 Machovich R. Choices among the possible reaction routes catalyzed by thrombin.  Ann N Y Acad Sci . 1986;  485 170-183
    PubMedGoogle Scholar
  • 11 Stamler J S, Vaughan D E, Loscalzo J. et al . Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin.  Circ Res . 1989;  65 796-804
    PubMedGoogle Scholar
  • 12 Vita J A, Treasure C B, Nabel E G. et al . Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease.  Circulation . 1990;  81 491-497
    CrossrefPubMedGoogle Scholar
  • 13 Celermajer D S, Sorensen K E, Gooch V M. et al . Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.  Lancet . 1992;  340 1111-1115
    CrossrefPubMedGoogle Scholar
  • 14 Zeiher A M, Drexler H, Wollschager H. et al . Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis.  Circulation . 1991;  83 391-401
    CrossrefPubMedGoogle Scholar
  • 15 Celermajer D S, Sorensen K E, Bull C. et al . Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction.  J Am Coll Cardiol . 1994;  24 1468-1474
    CrossrefPubMedGoogle Scholar
  • 16 Freiman P C, Mitchell G G, Heistad D D. et al . Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates.  Circ Res . 1986;  58 783-789
    CrossrefPubMedGoogle Scholar
  • 17 Ludmer P L, Selwyn A P, Shook T L. et al . Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries.  N Engl J Med . 1986;  315 1046-1051
    CrossrefPubMedGoogle Scholar
  • 18 Adams M R, Robinson J, McCredie R. et al . Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis.  J Am Coll Cardiol . 1998;  32 123-127
    CrossrefPubMedGoogle Scholar
  • 19 Nabel E G, Selwyn A P, Ganz P. Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis.  J Am Coll Cardiol . 1990;  16 349-356
    PubMedGoogle Scholar
  • 20 Gordon J B, Ganz P, Nabel E G. et al . Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise.  J Clin Invest . 1989;  83 1946-1952
    CrossrefPubMedGoogle Scholar
  • 21 Goldstein J L, Kita T, Brown M S. Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia.  N Engl J Med . 1983;  309 288-296
    PubMedGoogle Scholar
  • 22 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s.  Nature . 1993;  362 801-809
    CrossrefPubMedGoogle Scholar
  • 23 Libby P. Molecular bases of the acute coronary syndromes.  Circulation . 1995;  91 2844-2850
    CrossrefPubMedGoogle Scholar
  • 24 Fuster V, Badimon L, Badimon J J. et al . The pathogenesis of coronary artery disease and the acute coronary syndromes (2).  N Engl J Med . 1992;  326 310-318
    CrossrefPubMedGoogle Scholar
  • 25 Arnman V, Nilsson A, Stemme S. et al . Expression of plasminogen activator inhibitor-1 mRNA in healthy, atherosclerotic and thrombotic human arteries and veins.  Thromb Res . 1994;  76 487-499
    CrossrefPubMedGoogle Scholar
  • 26 Hamsten A. Hemostatic function and coronary artery disease.  N Engl J Med . 1995;  332 677-678
    CrossrefPubMedGoogle Scholar
  • 27 Szczeklik A, Musial J, Undas A. et al . Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia.  Arterioscler Thromb Vasc Biol . 1996;  16 948-954
    PubMedGoogle Scholar
  • 28 Davi G, Ganci A, Averna M. et al . Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia.  Thromb Haemost . 1995;  74 1015-1019
    PubMedGoogle Scholar
  • 29 Jayakody L, Senaratne M, Thomson A. et al . Endothelium-dependent relaxation in experimental atherosclerosis in the rabbit.  Circ Res . 1987;  60 251-264
    PubMedGoogle Scholar
  • 30 Chappell S P, Lewis M J, Henderson A H. Effect of lipid feeding on endothelium dependent relaxation in rabbit aortic preparations.  Cardiovasc Res . 1987;  21 34-38
    PubMedGoogle Scholar
  • 31 Kugiyama K, Kerns S A, Morrisett J D. et al . Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins.  Nature . 1990;  344 160-162
    CrossrefPubMedGoogle Scholar
  • 32 Ohara Y, Peterson T E, Harrison D G. Hypercholesterolemia increases endothelial superoxide anion production.  J Clin Invest . 1993;  91 2546-2551
    CrossrefPubMedGoogle Scholar
  • 33 Gryglewski R J, Palmer R M, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor.  Nature . 1986;  320 454-456
    CrossrefPubMedGoogle Scholar
  • 34 Liao J K, Shin W S, Lee W Y. et al . Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase.  J Biol Chem . 1995;  270 319-324
    CrossrefPubMedGoogle Scholar
  • 35 Ohara Y, Sayegh H S, Yamin J J. et al . Regulation of endothelial constitutive nitric oxide synthase by protein kinase C.  Hypertension . 1995;  25 415-420
    PubMedGoogle Scholar
  • 36 Bode-Boger S M, Boger R H, Kienke S. et al . Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits.  Biochem Biophys Res Commun . 1996;  219 598-603
    CrossrefPubMedGoogle Scholar
  • 37 Vallance P, Leone A, Calver A. et al . Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure.  Lancet . 1992;  339 572-575
    CrossrefPubMedGoogle Scholar
  • 38 Joris I, Zand T, Nunnari J J. et al . Studies on the pathogenesis of atherosclerosis. I. Adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats.  Am J Pathol . 1983;  113 341-358
    PubMedGoogle Scholar
  • 39 Mata P, Alonso R, Lopez-Farre A. et al . Effect of dietary fat saturation on LDL oxidation and monocyte adhesion to human endothelial cells in vitro.  Arterioscler Thromb Vasc Biol . 1996;  16 1347-1355
    PubMedGoogle Scholar
  • 40 Cybulsky M I, Gimbrone M A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis.  Science . 1991;  251 788-791
    PubMedGoogle Scholar
  • 41 Kinlay S, Selwyn A P, Delagrange D. et al . Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points.  Curr Opin Lipidol . 1996;  7 389-397
    PubMedGoogle Scholar
  • 42 Xu X P, Meisel S R, Ong J M. et al . Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages.  Circulation . 1999;  99 993-998
    PubMedGoogle Scholar
  • 43 Radomski M W, Palmer R M, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets.  Br J Pharmacol . 1987;  92 181-187
    PubMedGoogle Scholar
  • 44 Boulanger C M, Tanner F C, Bea M L. et al . Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium.  Circ Res . 1992;  70 1191-1197
    PubMedGoogle Scholar
  • 45 Arman V, Nilsson A, Stemme S. et al . Expression of plasminogen activator inhibitor-1 mRNA in healthy, atherosclerotic and thrombotic human arteries and veins.  Thromb Res . 1994;  76 487-499
    CrossrefPubMedGoogle Scholar
  • 46 Libby P. Current concepts of the pathogenesis of the acute coronary syndromes.  Circulation . 2001;  104 365-372
    CrossrefPubMedGoogle Scholar
  • 47 Slowik M R, Min W, Ardito T. et al . Evidence that tumor necrosis factor triggers apoptosis in human endothelial cells by interleukin-1-converting enzyme-like protease-dependent and -independent pathways.  Lab Invest . 1997;  77 257-267
    PubMedGoogle Scholar
  • 48 Ohara Y, Peterson T E, Harrison D G. Hypercholesterolemia increases endothelial superoxide anion production.  J Clin Invest . 1993;  91 2546-2551
    CrossrefPubMedGoogle Scholar
  • 49 Peng H B, Libby P, Liao J K. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B.  J Biol Chem . 1995;  270 14214-14219
    CrossrefPubMedGoogle Scholar
  • 50 Thurberg B, Collins T. The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis.  Curr Opin Lipidol . 1998;  9 387-396
    PubMedGoogle Scholar
  • 51 Joannides R, Haefeli W E, Linder L. et al . Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo.  Circulation . 1995;  91 1314-1319
    CrossrefPubMedGoogle Scholar
  • 52 Drexler H, Zeiher A M. Progression of coronary endothelial dysfunction in man and its potential clinical significance.  Basic Res Cardiol . 1991;  86 (suppl 2) 223-232
    PubMedGoogle Scholar
  • 53 Creager M A, Cooke J P, Mendelsohn M E. et al . Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans.  J Clin Invest . 1990;  86 228-234
    CrossrefPubMedGoogle Scholar
  • 54 Anderson T J, Uehata A, Gerhard M D. et al . Close relation of endothelial function in the human coronary and peripheral circulations.  J Am Coll Cardiol . 1995;  26 1235-1241
    CrossrefPubMedGoogle Scholar
  • 55 Nobuyoshi M, Tanaka M, Nosaka H. et al . Progression of coronary atherosclerosis: is coronary spasm related to progression?.  J Am Coll Cardiol . 1991;  18 904-910
    CrossrefPubMedGoogle Scholar
  • 56 Murakami T, Mizuno S, Kaku B. Clinical morbidities in subjects with Doppler-evaluated endothelial dysfunction of coronary artery.  J Am Coll Cardiol . 1998;  31 419A
    PubMedGoogle Scholar
  • 57 Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease.  Circulation . 2001;  104 2673-2678
    CrossrefPubMedGoogle Scholar
  • 58 Suwaidi J A, Hamasaki S, Higano S T, Nishimura R N, Holmes Jr R D, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.  Circulation . 2000;  101 948-954
    CrossrefPubMedGoogle Scholar
  • 59 Halcox J PJ, Schenke W H, Zalos G. et al . Prognostic value of coronary vascular endothelial dysfunction.  Circulation . 2002;  106 653-658
    CrossrefPubMedGoogle Scholar
  • 60 Aikawa M, Sugiyama S, Hill C C. et al . Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma.  Circulation . 2002;  106 1390-1396
    CrossrefPubMedGoogle Scholar
  • 61 Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells.  Arterioscler Thromb Vasc Biol . 2000;  20 556-562
    PubMedGoogle Scholar
  • 62 Treasure C B, Klein J L, Weintraub W S. et al . Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary disease.  N Engl J Med . 1995;  332 481-487
    CrossrefPubMedGoogle Scholar
  • 63 Marx N, Sukhova G K, Collins T. et al . PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells.  Circulation . 1999;  99 3125-3131
    PubMedGoogle Scholar
  • 64 Marx N, Mackman N, Schonbeck U. et al . PPARalpha activators inhibit tissue factor expression and activity in human monocytes.  Circulation . 2001;  103 213-219
    PubMedGoogle Scholar
  • 65 Neve B P, Corseaux D, Chinetti G. et al . PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.  Circulation . 2001;  103 207-212
    PubMedGoogle Scholar
  • 66 Marx N, Sukhova G, Murphy C et al. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro.  Am J Pathol . 1998;  153 17-23
    PubMedGoogle Scholar
  • 67 Staels B, Koenig W, Habib A. et al . Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.  Nature . 1998;  393 790-793
    CrossrefPubMedGoogle Scholar
  • 68 Marx N, Bourcier T, Sukhova G K. et al . PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease.  Arterioscler Thromb Vasc Biol . 1999;  19 546-551
    PubMedGoogle Scholar